Clinical Trial Update: Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating VG161 for advanced bone and soft tissue sarcoma and is currently recruiting; sponsor CNBG-Virogin Biotech (Shanghai) Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• VG161

Snippet

Sponsor: CNBG-Virogin Biotech (Shanghai) Ltd. | Conditions: Sarcoma | Phase 2 | Status: RECRUITING